Using PET/CT scans to evaluate treatment in patients with peritoneal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study investigates the use of repeated FDG-PET/CT scans in 16 patients suffering from peritoneal metastasis due to abdominal cancers who are being treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). The study aims to assess the feasibility and effectiveness of these scans in evaluating treatment response, as current methods rely on invasive biopsies. By exploring non-invasive imaging techniques, the study seeks to optimize patient selection and improve response assessment for future treatment strategies. The research is conducted at the Odense PIPAC Center, focusing on a multidisciplinary approach to patient care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with synchronous or metachronous histology or cytology proven GC, PC, CRC, or OC with clinical evidence of PM.
* Patients who are eligible for and offered PIPAC at the discretion of the dedicated multidisciplinary tumor conference and subsequent out-patient evaluation at Odense PIPAC Center
* Patients with a maximum of one extra-peritoneal metastasis at CT dated within one month of inclusion.
* Patients in Eastern Cooperative Oncology Group performance status 0-1.
* Patients \>18 years of age.
* Patients must be able to give mandatory oral and written consent in Danish.

Exclusion Criteria:

* Concomitant systemic chemotherapy (bidirectional treatment).
* Known allergies to contrast dye.
* Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the trial, or may influence the results.

Where it's running

• Odense PIPAC Center
  Odense, Funen, Denmark Recruiting

Study contacts

• Study coordinator: Signe Rønsholdt, MD
• Email: signe.r.rasmussen@rsyd.dk
• Phone: 0045 65411857

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Heated versus aerosolized chemotherapy delivered into the abdomen for cancer that has spread to the peritoneum

  This study will test whether heated (HIPEC) or aerosolized (PIPAC) mitomycin-based chemotherapy given into the abdomen works better and is safer for adults whose cancer has spread to the peritoneum.

  Recruiting Phase 2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07282834

• Direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal and gastrointestinal tumors

  This trial will try a single direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal tumors to see if it is safe for adults with advanced metastatic gastrointestinal or peritoneal cancers who have not responded to standard treatments.

  Recruiting Phase 1 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07001592

• Pressurized Chemotherapy for High Risk Colon Cancer Patients

  This study is testing a new type of chemotherapy for patients with high-risk colon cancer to see if it can help prevent cancer from coming back after surgery and standard treatment.

  Recruiting Phase 2 Odense University Hospital · Odense · NCT03280511

• Next Generation Delivery System (NGDS) for SBRT in thorax and upper abdomen

  A study tests a new machine to deliver SBRT more quickly and comfortably for adults with thoracic or upper abdominal cancers.

  Recruiting at 2 sites Varian, a Siemens Healthineers Company · St Louis, Missouri and 1 other locations · NCT07824583

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Raludotatug Deruxtecan with or without Bevacizumab for advanced ovarian, peritoneal, or fallopian tube cancer

  This trial tests whether adding raludotatug deruxtecan (R-DXd) to or without bevacizumab helps people with advanced ovarian cancer that progressed after PARP-inhibitor maintenance.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Fountain Valley, California and 6 other locations · NCT07743164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.